1
|
Cancer Research UK: Worldwide cancer
statistics. Cancer statistics; 2014, http://www.cancerresearchuk.org/cancerinfo/cancerstats/world/.
Accessed April 26, 2015.
|
2
|
Ferlay J, Shin H, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Cueva P and Yépez J: Cancer epidemiology
in Quito 2003–2005. Quito, Ecuador: National Cancer Registry (NCR),
SOLCA; 2009
|
5
|
World Health Organization: International
Agency for Research on Cancer, GLOBOCAN 2012: Estimated cancer
incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx.
Accessed April 26, 2015.
|
6
|
Faber PW, Kuiper GG, van Rooij HC, van der
Korput JA, Brinkmann AO and Trapman J: The N-terminal domain of the
human androgen receptor is encoded by one large exon. Mol Cell
Endocrinol. 61:257–262. 1989. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sleddens HF, Oostra BA, Brikmann AO and
Trapman J: Trinucleotode (GGN) repeat polymorphism in the human
androgen receptor (AR) gene. Hum Mol Genet. 2:4931993. View Article : Google Scholar
|
8
|
Mangelsdorf DJ, Thummel C, Beato M,
Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M,
Chambon P and Evans RM: The nuclear receptor superfamily: The
second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
|
9
|
Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L
and Yong EL: Long polyglutamine tracts in the androgen receptor are
associated with reduced trans-activation, impaired sperm production
and male infertility. J Clin Endocrinol Metab. 82:3777–3782.
1997.PubMed/NCBI
|
10
|
Irvine RA, Yu MC, Ross RK and Coetzee GA:
The CAG and GGC microsatellites of the androgen receptor gene are
linkage disequilibrium in men with prostate cancer. Cancer Res.
55:1937–1940. 1995.PubMed/NCBI
|
11
|
Giovannucci E, Stampfer MJ, Kritivas K,
Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH and Kantoff PW:
The CAG repeat within the androgen receptor gene and its
relationship to prostate cancer. Proc Natl Acad Sci USA.
94:3320–3323. 1997. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ingles SA, Ross RK, Yu MC, Irvine RA, La
Pera G, Haile RW and Coetzee GA: Association of prostate cancer
risk with genetic polimorphims in vitamin D receptor and androgen
receptor. J Natl Cancer Inst. 89:166–170. 1997. View Article : Google Scholar : PubMed/NCBI
|
13
|
Stanford JL, Just JJ, Gibbs M, Wicklund
KG, Neal CL, Blumenstein BA and Ostrander EA: Polymorphic repeats
in the androgen receptor gene: Molecular markers of prostate cancer
risk. Cancer Res. 57:1194–1198. 1997.PubMed/NCBI
|
14
|
Hakimi JM, Schoenberg MP, Rondinelli RH,
Piantadosi S and Barrack ER: Androgen receptor variants with short
glutamine or glycine repeats may identify unique subpopulations of
men with prostate cancer. Clin Cancer Res. 3:1599–1608. 1997.
|
15
|
Cicek MS, Conti DV, Curran A, Neville PJ,
Paris PL, Casey G and Witte JS: Association of prostate cancer risk
and aggressiveness to androgen pathway genes: SRD5A2, CYP17 and the
AR. Prostate. 59:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Salinas CA, Austin MA, Ostrander EO and
Stanford JL: Polymorphisms in the androgen receptor and the
prostate-specific antigen genes and prostate cancer risk. Prostate.
65:58–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Kristal AR, Price DK, Till C, Schenk JM,
Neuhouser ML, Ockers S, Lin DW, Thompson IM and Figg WD: Androgen
receptor CAG repeat length is not associated with the risk of
incident symptomatic begin prostatic hyperplasia: Results from the
prostate cancer prevention trial. Prostate. 70:584–590. 2010.
|
18
|
Platz EA, Giovannucci E, Dahl DM,
Krithivas K, Hennekens CH, Brown M, Stampfer MJ and Kantoff PW: The
androgen receptor gene GGN microsatellite and prostate cancer risk.
Cancer Epidemiol Biomarkers Prev. 7:379–384. 1998.PubMed/NCBI
|
19
|
Ding D, Xu L, Menon M, Reddy GP and
Barrack ER: Effect of GGC (glycine) repeat length polymorphism in
the human androgen receptor on androgen action. Prostate.
62:133–139. 2005. View Article : Google Scholar
|
20
|
Edwards SM, Badzioch MD, Minter R, Hamoudi
R, Collins N, Ardern-Jones A, Dowe A, Osborne S, Kelly J, Shearer
R, et al: Androgen receptor polymorphisms: Association with
prostate cancer risk, relapse and overall survival. Int J Cancer.
84:458–465. 1999. View Article : Google Scholar : PubMed/NCBI
|
21
|
Chen C, Lamhanzi N, Weis NS, Etzioni R,
Dightman DA, Barnett M, DiTommaso D and Goodman G: Androgen
receptor polymorphisms and the incidence of prostate cancer. Cancer
Epidemiol Biomarkers Prev. 11:1033–1040. 2002.PubMed/NCBI
|
22
|
López-Cortés A, Echeverría C, Oña-Cisneros
F, Sánchez ME, Herrera C, Cabrera-Andrade A, Rosales F, Ortiz M and
Paz-Y-Miño C: Breast cancer risk associated with gene expression
and genotype polymorphisms of the folate-metabolizing MTHFR gene: A
case-control study in a high altitude Ecuadorian mestizo
population. Tumor Biol. 36:6451–6461. 2015. View Article : Google Scholar
|
23
|
Ellegren H: Microsatellites: Simple
sequences with complex evolution. Nat Rev Genet. 5:435–445. 2004.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Albà MM and Guigó R: Comparative analysis
of amino acid repeats in rodents and humans. Genome Res.
14:549–555. 2004. View Article : Google Scholar : PubMed/NCBI
|
25
|
Sawaya ME and Shalita AR: Androgen
receptor polymorphisms (CAG repeat lengths) in androgenetic
alopecia, hirsutism and acne. J Cutan Med Surg. 3:9–15.
1998.PubMed/NCBI
|
26
|
Shah NA, Antoine HJ, Pall M, Taylor KD,
Azziz R and Goodarzi MO: Association of androgen receptor CAG
repeat polymorphism and polycystic ovary syndrome. J Clin
Endocrinol Metab. 93:1939–1945. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Mehdipour P, Pirouzpanah S, Kheirollahi M
and Atri M: Androgen receptor gene CAG repeat polymorphism and
breast cancer risk in Iranian women: A case-control study. Breast
J. 17:39–46. 2011. View Article : Google Scholar
|
28
|
MacLean HE, Choi WT, Rekaris G, Warne GL
and Zajac JD: Abnornal androgen receptor binding affinity in
subjects with Kennedy's disease (spinal and bulbar muscular
atrophy). J Clin Endocrinol Metab. 80:508–516. 1995.PubMed/NCBI
|
29
|
Fesaĭ O, Kravchenko SA, Tyrkus MIa, Makukh
GV, Zinchenko VM, Strelko GV and Livshits LA: Androgen receptor CAG
gene polymorphism in men with azoospermia and oligozoospermia in
Ukraine. Tsitol Genet. 43:45–51. 2009.In Russian.
|
30
|
Radpour R, Rezaee M, Tavasoly A, Solati S
and Saleki A: Association of long polyglycine tracts (GGN repeats)
in exon 1 of the androgen receptor gene with cryptorchidism and
penile hypospadias in Iranian patients. J Androl. 28:164–169. 2007.
View Article : Google Scholar
|
31
|
Aschim EL, Nordenskjöld A, Giwercman A,
Lundin KB, Ruhayel Y, Haugen TB, Grotmol T and Giwercman YL:
Linkage between cryptorchidism, hypospadias and GGN repeat length
in the androgen receptor gene. J Clin Endocrinol Metab.
89:5105–5109. 2004. View Article : Google Scholar : PubMed/NCBI
|
32
|
Sartor O, Zheng Q and Eastham JA: Androgen
receptor gene CAG repeat length varies in a race-specific fashion
in men without prostate cancer. Urology. 53:378–380. 1999.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Kittles RA, Young D, Weinrich S, Hudson J,
Argyropoulos G, Ukoli F, Adams-Campbell L and Dunston GM: Extent of
linkage disequilibrium between the androgen receptor gene CAG and
GGC repeats in human populations: Implications for prostate cancer
risk. Hum Genet. 109:253–261. 2001. View Article : Google Scholar : PubMed/NCBI
|
34
|
Krausz C: An encore for the repeats: New
insights into an old genetic variant. J Clin Endocrinol Metab.
97:764–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Paz-y-Miño C, Witte T, Robles P,
Llumipanta W, Díaz M and Arévalo M: Association among polymorphisms
in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate
cancer risk, and pathologic characteristics of prostate tumors in
an Ecuadorian population. Cancer Genet Cytogenet. 189:71–76. 2009.
View Article : Google Scholar : PubMed/NCBI
|
36
|
López-Cortés A, Jaramillo-Koupermann G,
Muñoz MJ, Cabrera A, Echeverría C, Rosales F, Vivar N and
Paz-y-Miño C: Genetic polymorphisms in MTHFR (C677T, A1298C), MTR
(A2756G) and MTRR (A66G) genes associated with pathological
characteristics of prostate cancer in the Ecuadorian population. Am
J Med Sci. 346:447–454. 2013. View Article : Google Scholar : PubMed/NCBI
|
37
|
Ribeiro ML, Santos A, Carvalho-Salles AB
and Hackel C: Allelic frequencies of six polymorphic markers for
risk of prostate cancer. Braz J Med Biol Res. 35:205–213. 2002.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Madjunkova S, Eftimov A, Georgiev V,
Petrovski D, Dimovski A and Plaseska-Karanfilska D: CAG repeat
number in the androgen receptor gene and prostate cancer. Balkan J
Med Genet. 15:31–36. 2012.PubMed/NCBI
|
39
|
Beilin J, Harewood L, Frydenberg M,
Mameghan H, Martyres RF, Farish SJ, Yue C, Deam DR, Byron KA and
Zajac JD: A case-control study of the androgen receptor gene CAG
repeat polymorphism in Australian prostate carcinoma subjects.
Cancer. 92:941–949. 2001. View Article : Google Scholar : PubMed/NCBI
|
40
|
Esteban E, Rodon N, Via M, Gonzalez-Perez
E, Santamaria J, Dugoujon JM, Chennawi FE, Melhaoui M, Cherkaoui M,
Vona G, et al: Androgen receptor CAG and GGC polymorphisms in
Mediterraneans: Repeat dynamics and population relationships. J Hum
Genet. 51:129–136. 2006. View Article : Google Scholar
|
41
|
Baeta M, Núñez C, Aznar JM, Sosa C,
Casalod Y, Bolea M, González-Andrade F, de Pancorbo MM and
Martínez-Jarreta B: Analysis of 10 X-STRs in three population
groups from Ecuador. Forensic Sci Int Genet. 7:e19–e20. 2013.
View Article : Google Scholar
|
42
|
Hsing AW, Gao YT, Wu G, Wang X, Deng J,
Chen YL, Sesterhenn IA, Mostofi FK, Benichou J and Chang C:
Polymorphic CAG and GGN repeat lengths in the androgen receptor
gene and prostate cancer risk: A population-based case-control
study in China. Cancer Res. 60:5111–5116. 2000.PubMed/NCBI
|
43
|
Lange EM, Chen H, Brierley K, Livermore H,
Wojno KJ, Langefeld CD, Lange K and Cooney KA: The polymorphic exon
1 androgen receptor CAG repeat in men with a potential inherited
predisposition to prostate cancer. Cancer Epidemiol Biomarkers
Prev. 9:439–442. 2000.PubMed/NCBI
|
44
|
Price DK, Chau CH, Till C, Goodman PJ,
Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, et
al: Androgen receptor CAG repeat length and association with
prostate cancer risk: Results from the prostate cancer prevention
trial. J Urol. 184:2297–3302. 2010. View Article : Google Scholar : PubMed/NCBI
|
45
|
Giovannucci E: Is the androgen receptor
CAG repeat length significant for prostate cancer? Cancer Epidemiol
Biomarkers Prev. 11:985–986. 2002.PubMed/NCBI
|
46
|
Correa-Cerro L, Wöhr G, Häussler J,
Berthon P, Drelon E, Mangin P, Fournier G, Cussenot O, Kraus P,
Just W, et al: (CAG) nCAA and GGN repeats in the human androgen
receptor gene are not associated with prostate cancer in a
French-German population. Eur J Hum Genet. 7:357–362. 1999.
View Article : Google Scholar : PubMed/NCBI
|
47
|
Platz EA, Leitzmann MF, Rifai N, Kantoff
PW, Chen YC, Stampfer MJ, Willett WC and Giovannucci E: Sex steroid
hormones and the androgen receptor gene CAG repeat and subsequent
risk of prostate cancer in the prostate-specific antigen era.
Cancer Epidemiol Biomarkers Prev. 14:1262–1269. 2005. View Article : Google Scholar : PubMed/NCBI
|
48
|
Alptekin D, Izmirli M, Bayazit Y, Luleyap
HU, Yilmaz MB, Soyupak B, Erkoc MA and Tansug Z: Evaluation of the
effects of androgen receptor gene trinucleotide repeats and
prostate-specific antigen gene polymorphisms on prostate cancer.
Genet Mol Res. 11:1424–1432. 2012. View Article : Google Scholar : PubMed/NCBI
|
49
|
Narod SA, Dupont A, Cusan L, Diamond P,
Gomez JL, Suburu R and Labrie F: The impact of family history on
early detection of prostate cancer. Nat Med. 1:99–101. 1995.
View Article : Google Scholar : PubMed/NCBI
|
50
|
Monroe KR, Yu MC, Kolonel LN, Coetzee GA,
Wilkens LR, Ross RK and Henderson BE: Evidence of an X-linked or
recessive genetic component to prostate cancer risk. Nat Med.
1:827–829. 1995. View Article : Google Scholar : PubMed/NCBI
|